Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

Pfizer3,538 enrolled

Overview

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

All the patients whom an investigator prescribes the first Macugen® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Study Type

OBSERVATIONAL

Enrollment

3,538

Conditions

Macular Degeneration

Interventions

Pegaptanib sodiumDRUG

Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )".

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients need to be administered Macugen® in order to be enrolled in the surveillance. Exclusion Criteria: * Patients not administered Macugen®.

Outcomes

Primary Outcomes

Factors considered to affect the safety and/or efficacy of this drug.

Time frame: 2 years

The incidence of adverse drug reactions in this surveillance.

Time frame: 2 years

Adverse drug reaction not expected from the LPD (unknown adverse drug reaction).

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.